- Home
- QNRX vs PSTV Comparison
QNRX vs PSTV Comparison
Compare QNRX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- PSTV
- Stock Information
- Founded
- QNRX 2018
- PSTV 1996
- Country
- QNRX United States
- PSTV United States
- Employees
- QNRX N/A
- PSTV N/A
- Industry
- QNRX Medical/Dental Instruments
- PSTV Medical/Dental Instruments
- Sector
- QNRX Health Care
- PSTV Health Care
- Exchange
- QNRX Nasdaq
- PSTV Nasdaq
- Market Cap
- QNRX 2.5M
- PSTV 2.1M
- IPO Year
- QNRX N/A
- PSTV N/A
- Fundamental
- Price
- QNRX $0.24
- PSTV $1.16
- Analyst Decision
- QNRX
- PSTV Strong Buy
- Analyst Count
- QNRX 0
- PSTV 3
- Target Price
- QNRX N/A
- PSTV $11.17
- AVG Volume (30 Days)
- QNRX 567.3K
- PSTV 46.9M
- Earning Date
- QNRX 03-13-2025
- PSTV 03-27-2025
- Dividend Yield
- QNRX N/A
- PSTV N/A
- EPS Growth
- QNRX N/A
- PSTV N/A
- EPS
- QNRX N/A
- PSTV N/A
- Revenue
- QNRX N/A
- PSTV $5,824,000.00
- Revenue This Year
- QNRX N/A
- PSTV N/A
- Revenue Next Year
- QNRX N/A
- PSTV N/A
- P/E Ratio
- QNRX N/A
- PSTV N/A
- Revenue Growth
- QNRX N/A
- PSTV 18.54
- 52 Week Low
- QNRX $0.24
- PSTV $0.24
- 52 Week High
- QNRX $1.57
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- QNRX 32.92
- PSTV 51.22
- Support Level
- QNRX $0.28
- PSTV $1.01
- Resistance Level
- QNRX $0.32
- PSTV $1.77
- Average True Range (ATR)
- QNRX 0.02
- PSTV 0.37
- MACD
- QNRX 0.00
- PSTV 0.06
- Stochastic Oscillator
- QNRX 2.31
- PSTV 42.14
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).